Cargando…

End-of-treatment PET in early-stage Hodgkin lymphoma: valuable in addition to interim PET

Detalles Bibliográficos
Autores principales:	Chohan, Karan L., Young, Jason R., Lester, Scott, Moustafa, Muhamad Alhaj, Rosenthal, Allison, Tun, Han W., Hoppe, Bradford S., Johnston, Patrick B., Micallef, Ivana N., Habermann, Thomas M., Ansell, Stephen M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Fondazione Ferrata Storti 2022
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10230436/ https://www.ncbi.nlm.nih.gov/pubmed/36546451 http://dx.doi.org/10.3324/haematol.2022.282115

Ejemplares similares

A real-world study of combined modality therapy for early-stage Hodgkin lymphoma: too little treatment impacts outcome
por: Chohan, Karan L., et al.
Publicado: (2022)

Interim FDG-PET Scan in Hodgkin's Lymphoma: Hopes and Caveats
por: André, M., et al.
Publicado: (2011)

Interim-treatment quantitative PET parameters predict progression and death among patients with hodgkin's disease
por: Tseng, Diane, et al.
Publicado: (2012)

Interim FDG-PET/CT for therapy monitoring and prognostication in Hodgkin’s Lymphoma
por: Al-Ibraheem, Akram, et al.
Publicado: (2022)

Interobserver variability in interim PET assessment in Hodgkin lymphoma—reasons and solutions
por: Georgi, Thomas W., et al.
Publicado: (2023)

Quantitative assessment of interim PET in Hodgkin lymphoma: An evaluation of the qPET method in adult patients in the RAPID trial
por: Georgi, Thomas W., et al.
Publicado: (2020)

Outcomes of Patients With Classic Hodgkin Lymphoma Who Relapsed After Autologous Stem Cell Transplant
por: Tun, Aung M., et al.
Publicado: (2023)

Successful Non-Transplant Treatment of Double Hit Richter Transformation with Long-Term Remission
por: Seegobin, Karan, et al.
Publicado: (2021)

Explorative analyses on the value of interim PET for prediction of response in pediatric and adolescent non-Hodgkin lymphoma patients
por: Furth, Christian, et al.
Publicado: (2013)

Predictive value of interim PET/CT visual interpretation in the prognosis of patients with aggressive non-Hodgkin’s lymphoma
por: Liao, Cheng-Cheng, et al.
Publicado: (2017)

Classical Hodgkin Lymphoma: A Joint Clinical and PET Model to Predict Poor Responders at Interim Assessment
por: Triumbari, Elizabeth Katherine Anna, et al.
Publicado: (2022)

Consolidative radiotherapy for residual fluorodeoxyglucose activity on day +30 post CAR T-cell therapy in non-Hodgkin lymphoma
por: Saifi, Omran, et al.
Publicado: (2023)

Pediatric Hodgkin Lymphoma: Predictive value of interim (18)F-FDG PET/CT in therapy response assessment
por: Ferrari, Cristina, et al.
Publicado: (2017)

CT-based texture analysis potentially provides prognostic information complementary to interim fdg-pet for patients with hodgkin’s and aggressive non-hodgkin’s lymphomas
por: Ganeshan, B., et al.
Publicado: (2016)

Does Interim PET Scan After 2 Cycles of ABVD Predict Outcome in Hodgkin Lymphoma? Real-World Evidence
por: Seshachalam, Arun, et al.
Publicado: (2019)

P105: Decisional role of interim PET in relapsed/refractory classical Hodgkin Lymphoma treated with four begev cycles
por: Rusconi, Chiara, et al.
Publicado: (2022)

Importance of baseline PET/CT imaging on radiation field design and relapse rates in patients with Hodgkin lymphoma
por: Figura, Nick, et al.
Publicado: (2017)

Severe Insulin Resistance in a Patient Treated With Nivolumab and Brentuximab-Vedotin for Hodgkin Lymphoma
por: Tama, Elif, et al.
Publicado: (2023)

Outcomes of patients with stage I–II Hodgkin lymphoma who had uniform pre-treatment staging with PET/CT and treatment with limited field radiation therapy after chemotherapy
por: Frechette, Kelsey M., et al.
Publicado: (2022)

P1070: DECISIONAL ROLE OF INTERIM PET IN RELAPSED/REFRACTORY CLASSICAL HODGKIN LYMPHOMA TREATED WITH BEGEV CHEMOTHERAPY AS FIRST SALVAGE
por: Rusconi, Chiara, et al.
Publicado: (2023)

Paraneoplastic frosted branch angiitis as first sign of relapsed Hodgkin lymphoma
por: Alhaj Moustafa, Muhamad, et al.
Publicado: (2018)

The role of FDG-PET in Hodgkin lymphoma
por: Subocz, Edyta, et al.
Publicado: (2017)

FDG PET for therapy monitoring in Hodgkin and non-Hodgkin lymphomas
por: Barrington, Sally F., et al.
Publicado: (2017)

P108: Integrating baseline circulating tumor DNA with interim PET improves outcome prediction in relapsed/refractory classical Hodgkin lymphoma
por: Calabretta, Eleonora, et al.
Publicado: (2022)

Infused autograft lymphocyte to monocyte ratio predicts survival in classical Hodgkin lymphoma
por: Porrata, Luis F, et al.
Publicado: (2015)

Cross-Coupling Reactions as Valuable Tool for the Preparation of PET Radiotracers
por: Pretze, Marc, et al.
Publicado: (2011)

Comparable Efficacy of Reduced Dose Radiation Therapy for the Treatment of Early Stage Gastric Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue
por: Saifi, Omran, et al.
Publicado: (2021)

Comparing the accuracy of quantitative versus qualitative analyses of interim PET to prognosticate Hodgkin lymphoma: a systematic review protocol of diagnostic test accuracy
por: Procházka, Vít, et al.
Publicado: (2016)

Comparison of CT, PET, and PET/CT for Staging of Patients with Indolent Non-Hodgkin’s Lymphoma
por: Fueger, Barbara J., et al.
Publicado: (2009)

Macrophage Activation Led Acute Heart Failure Managed Successfully with Immunosuppression
por: Seegobin, Karan, et al.
Publicado: (2021)

Intravascular Large B Cell Lymphoma with CNS Involvement Successfully Treated with High-Dose Methotrexate and High-Dose Ara-C Based CNS-Directed Chemoimmunotherapy Alternating with Anthracycline Based Chemoimmunotherapy
por: Wang, Jing, et al.
Publicado: (2022)

Metabolic PET/CT analysis of aggressive Non-Hodgkin lymphoma prior to Axicabtagene Ciloleucel CAR-T infusion: predictors of progressive disease, survival, and toxicity
por: Breen, William G., et al.
Publicado: (2023)

Primary HHV-8 (-) Effusion-Based Non-Germinal Center B Cell Diffuse Large B Cell Lymphoma Successfully Treated with Standard Anthracycline-Based Chemoimmunotherapy
por: Kuhlman, Justin, et al.
Publicado: (2021)

(90)Yttrium Ibritumomab Tiuxetan (Zevalin) for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: A Report of 5 Cases
por: Wang, Jing, et al.
Publicado: (2023)

Clinical characteristics, prognostic indicators, and survival outcomes in intravascular lymphoma: Mayo Clinic experience (2003–2018)
por: Seegobin, Karan, et al.
Publicado: (2022)

PET2 response associated with survival in newly diagnosed diffuse large B-cell lymphoma: results of two independent prospective cohorts
por: Desai, Sanjal H., et al.
Publicado: (2022)

Prognostic value of lesion dissemination in doxorubicin, bleomycin, vinblastine, and dacarbazine‐treated, interimPET‐negative classical Hodgkin Lymphoma patients: A radio‐genomic study
por: Durmo, Rexhep, et al.
Publicado: (2022)

PET/MRI for staging patients with Hodgkin lymphoma: equivalent results with PET/CT in a prospective trial
por: Picardi, M., et al.
Publicado: (2021)

Interleukin-15 Affects Patient Survival through Natural Killer Cell Recovery after Autologous Hematopoietic Stem Cell Transplantation for Non-Hodgkin Lymphomas
por: Porrata, Luis F., et al.
Publicado: (2010)

Day 100 Peripheral Blood Absolute Lymphocyte/Monocyte Ratio and Survival in Classical Hodgkin's Lymphoma Postautologous Peripheral Blood Hematopoietic Stem Cell Transplantation
por: Porrata, Luis F., et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_jdi4l2fr8qo3hsdi0v4lcbhfpb